Table 1.
Baseline Demographics of the 202 Patients in this Study
| Variable | No. (%) | Low TILs |
Moderate TILs |
High TILs |
P |
|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | |||
| Age, yrs.: mean ± SD | 60.74 ± 13.48 | 0.906 | |||
| ≤60 | 97 (48.0%) | 32 (46.4%) | 36 (48.0%) | 29 (50.0%) | |
| >60 | 105 (52.0%) | 37 (53.6%) | 39 (52.0%) | 29 (50.0%) | |
| Sex | 0.097 | ||||
| Male | 134 (66.3%) | 51 (73.9%) | 43 (57.3%) | 40 (69.0%) | |
| Female | 68 (33.7%) | 18 (26.1%) | 32 (42.7%) | 18 (31.0%) | |
| cT stage | 0.008 | ||||
| T1 | 32 (15.8%) | 8 (11.6%) | 12 (16.0%) | 12 (20.7%) | |
| T2 | 53 (26.2%) | 12 (17.4%) | 23 (30.7%) | 18 (31.0%) | |
| T3 | 38 (18.8%) | 9 (13.0%) | 15 (20.0%) | 14 (24.1%) | |
| T4 | 79 (39.2%) | 40 (58.0%) | 25 (33.3%) | 14 (24.1%) | |
| pN stage | 0.130 | ||||
| N0 | 120 (59.4%) | 36 (52.2%) | 44 (58.7%) | 40 (69.0%) | |
| N1 | 30 (14.9%) | 9 (13.0%) | 15 (20.0%) | 6 (10.3%) | |
| N2 | 52 (25.7%) | 24 (34.8%) | 16 (21.3%) | 12 (20.7%) | |
| N3 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Site | 0.112 | ||||
| Oral cavity | 191 (94.6%) | 62 (89.9%) | 72 (96.0%) | 57 (98.3%) | |
| Oropharynx | 11 (5.4%) | 7 (10.1%) | 3 (4.0%) | 1 (1.7%) | |
| Smoking history | 0.042 | ||||
| Smoker | 93 (46.0%) | 39 (56.5%) | 25 (33.3%) | 29 (50.0%) | |
| Nonsmoker | 104 (51.5%) | 28 (40.6%) | 48 (64.0%) | 28 (48.3%) | |
| Missing | 5 (2.5%) | 2 (2.9%) | 2 (2.7%) | 1 (1.7%) | |
| Alcohol history | 0.048 | ||||
| Drinker | 58 (28.7%) | 26 (37.7%) | 13 (17.3%) | 19 (32.8%) | |
| Nondrinker | 139 (68.8%) | 41 (59.4%) | 60 (80.0%) | 38 (65.5%) | |
| Missing | 5 (2.5%) | 2 (2.9%) | 2 (2.7%) | 1 (1.7%) | |
| Perineural invasion | 0.150 | ||||
| Absence | 146 (72.3%) | 47 (68.1%) | 50 (66.7%) | 49 (84.5%) | |
| Presence | 23 (11.4%) | 10 (14.5%) | 9 (12.0%) | 4 (6.9%) | |
| Missing | 33 (16.3%) | 12 (17.4%) | 16 (21.3%) | 5 (8.6%) | |
| Vascular emboli | 0.286 | ||||
| Absence | 164 (81.2%) | 55 (79.7%) | 58 (77.3%) | 51 (87.9%) | |
| Presence | 5 (2.5%) | 2 (2.9%) | 1 (1.3%) | 2 (3.4%) | |
| Missing | 33 (16.3%) | 12 (17.4%) | 16 (21.3%) | 5 (8.6%) | |
| Diffuse infiltration | 0.261 | ||||
| Absence | 137 (67.8%) | 48 (69.6%) | 45 (60.0%) | 44 (75.9%) | |
| Presence | 32 (15.8%) | 9 (13.0%) | 14 (18.7%) | 9 (15.5%) | |
| Missing | 33 (16.3%) | 12 (17.4%) | 16 (21.3%) | 5 (8.6%) | |
| Microscopic ECS | 0.012 | ||||
| Absence | 160 (79.2%) | 50 (72.5%) | 57 (76.0%) | 53 (91.4%) | |
| Presence | 9 (4.5%) | 7 (10.1%) | 2 (2.7%) | 0 (0.0%) | |
| Missing | 33 (16.3%) | 12 (17.4%) | 16 (21.3%) | 5 (8.6%) | |
| Adjuvant radiotherapy | 0.012 | ||||
| Yes | 142 (70.3%) | 56 (81.2%) | 53 (70.7%) | 55 (68.8%) | |
| No | 60 (29.7%) | 13 (18.8%) | 22 (29.3%) | 25 (31.2%) | |
| p16 status* | 0.406 | ||||
| p16+ | 2 (18.2%) | 1 (14.3%) | 1 (33.3%) | 0 (0.0%) | |
| p16− | 8 (72.7%) | 6 (85.7%) | 1 (33.3%) | 1 (100.0%) | |
| Missing | 1 (9.1%) | 0 (0.0%) | 1 (33.3%) | (0.0%) |
Note: * p16 status was evaluated only in patients with oropharyngeal squamous cell carcinoma.